Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1Gynecologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 464Lung Neoplasms 147Melanoma 92Squamous Cell Carcinoma of Head and Neck 70Carcinoma, Renal Cell 63Neoplasms 61Colorectal Neoplasms 61Triple Negative Breast Neoplasms 48Neoplasm Metastasis 48Parkinson Disease 4, Autosomal Dominant Lewy Body 44Ovarian Neoplasms 42Stomach Neoplasms 39Small Cell Lung Carcinoma 39Pancreatic Neoplasms 39Carcinoma, Transitional Cell 38Breast Neoplasms 38Head and Neck Neoplasms 34Uterine Cervical Neoplasms 30Endometrial Neoplasms 30Urinary Bladder Neoplasms 26Esophageal Neoplasms 24Carcinoma, Hepatocellular 24Mesothelioma 21Mesothelioma, Malignant 18Kidney Neoplasms 15Prostatic Neoplasms 14Adenocarcinoma of Lung 14Carcinoma 13Colonic Neoplasms 12Cholangiocarcinoma 12

Interventions

spartalizumab 1pembrolizumab 1Oxaliplatin 1Nivolumab 1Leucovorin 1Fulvestrant 1Fluorouracil 1E7046 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Spinocerebellar Degenerations × pembrolizumab × Thoracic × Clear all
NCT04432857 2024-06-27

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Adlai Nortye Biopharma Co., Ltd.

Phase 1 Active not recruiting
63 enrolled
BreastGastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Spinocerebellar Degenerations, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡